Torsten Gerriet Blum (Berlin, Germany), Georgia Hardavella (Aghia Paraskevi, Athens, Greece), Chair to be confirmed
Novel survey tool used to assess priorities of lung cancer patients and carers
Mathew Peters (Concord, Australia), Matthew Peters, Aoife McNamara, Win Boerckel, Albert Van Eijk, Jesme Fox
|   |
Lung cancer consultation letter to patient - Do you feel informed and cared?
Syed Mehdi (Bolton, United Kingdom), Syed B. Mehdi, Ram Sundar, Neil Bayman
| |
Reducing the rate of emergency presentation in lung cancer
Michelle Huxley (Crewe, United Kingdom), Michelle Huxley, Sue Stubbs, Catherine Mills, Duncan Fullerton, Syed M.H. Kazmi
| |
Epithelial growth factor receptor (EGFR) mutation status and the treatment of non-small cell lung cancer (NSCLC): A population based quality assurance analysis
Niels-Christian Gerner Hansen (Odense C, Denmark), Niels-Chr. G. Hansen, Christian B. Laursen, Karin H. Hansen, Karen E. Olsen
| |
Effect of incidental FDG findings at extrapulmonary locations on duration of diagnosis and time to treatment in patients staged for lung cancer: Retrospective analysis
Yavuz Havlucu (Manisa, Turkey), Yavuz Havlucu, Pinar Celik, Fikret Kurhan, Tugba Goktalay, Aysin Sakar Coskun, Arzu Yorgancioglu
| |
Should resection rate increase when PET-CT use increases? An analysis of PET-CT use in large UK lung cancer network 2011 - 2013
Matthew Evison (Manchester, United Kingdom), Haval Balata, Evison Matthew, Julie Morris, Haider Al-Najjar, Phil Barber, Philip Crosbie, Richard Booton
| |
European mapping of EGFR mutation test and EGFR tyrosine kinase inhibitors availability in thoracic oncology
Mélodie Carbonnaux (Lyon, France), Mélodie Carbonnaux, Pierre-Jean Souquet, Arnaud Scherpereel, Sébastien Couraud
| |
Low histological confirmation rate in a District General Hospital (DGH)– exploring the reasons why
Michelle Huxley (Crewe, United Kingdom), Michelle Huxley, Sue Stubbs, Syed M.H. Kazmi
| |
Is time from "referral to diagnosis" in lung cancer pathway affected by diagnostic test delays?
Michelle Huxley (Crewe, United Kingdom), Michelle Huxley, Sue Stubbs, Lynn Thomas, Gerhard Bockeler, Duncan Fullerton, Syed M.H. Kazmi
| |
Lung cancer and socioeconomic status: Differences in demographics, stage, treatment and mortality in a lung cancer centre
Eve Denton (Mornington, Australia), Eve Denton, Matthew Conron, David Hart, Gavin Wright, Rory Wolfe, Prue Russell
| |
Population’s understanding and degree of participation of a screening lung cancer programme
María Sánchez-Carpintero Abad (Orkoien (Navarra), Spain), María Sánchez-Carpintero Abad, Leticia García Rodriguez, Marta López Cañadas, Franisco Roig Vázquez
| |
Improving survival for NSCLC patients in the national lung cancer audit
Ian Woolhouse (Birmingham, United Kingdom), Paul Beckett, Ian Woolhouse, Mick Peake, Laila Tata, Aamir Khakwani
| |
Defining a standard set of patient-centered outcomes for patients with lung cancer
Jan van Meerbeeck (Ghent, Belgium), Jan P. Van Meerbeeck, Kimberley S. Mak, Annelotte Van Bommel, Caleb Stowell, Mick Peake
| |
Follow -up results, malignancy rates and malignancy determinants of the pulmonary nodules that evaluated in multidisciplinary thoracic oncology tumour board
Özge Öztürk (Ankara, Turkey), Özge Öztürk, Ahmet Ugur Demir, Ziya Toros Selçuk
| |
Lung cancer, has it changed in the last ten years?
David Bravo Blanco (Llodio, Spain), David Bravo Blanco, Olatz Llaguno Ochandiano, Igor Murga Arizabaleta, Ester Marijuán Gómez, Laura Tomás López, Jose Luis Lobo Beristain, Patricia Sobradillo Ecenarro
| |
Is there equitable access to PET-CT for lung cancer patients across a large UK cancer network; a retrospective study of 4597 patients
Haval Balata (Manchester, United Kingdom), Haval Balata, Matthew Evison, Julie Morris, Haider Al-Najjar, Phil Barber, Philip Crosbie, Richard Booton
| |
Analysis of PET-CT use across a UK cancer network: Are we adhering to NICE guidelines?
Haval Balata (Manchester, United Kingdom), Haval Balata, Matthew Evison, Haider Al-Najjar, Phil Barber, Richard Booton, Philip Crosbie
| |